Добірка наукової літератури з теми "Infections à coronavirus – traitement médicamenteux"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Infections à coronavirus – traitement médicamenteux".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Infections à coronavirus – traitement médicamenteux":
Dumas, G., N. Bigé, V. Lemiale, and E. Azoulay. "Patients immunodéprimés, quel pathogène pour quel déficit immunitaire ? (en dehors de l’infection à VIH)." Médecine Intensive Réanimation 27, no. 4 (July 2018): 344–66. http://dx.doi.org/10.3166/rea-2018-0056.
Sanogo, M., Y. Cissoko, RGT Tonnang, I. Coulibaly, H. Camara, A. Sacko, and Et Al. "Évaluation des pratiques d'hygiène et de prévention de la maladie à coronavirus en milieu hospitalier : Cas des centres d'isolement et de traitement du covid19 au Centre Hospitalo-Universitaire du Point G (CHU-PG) au Mali." Revue Malienne d'Infectiologie et de Microbiologie 16, no. 1 (January 31, 2021): 16–24. http://dx.doi.org/10.53597/remim.v16i1.1755.
Benamara, D., Z. Benamara, and S. Benamara. "Bénéfices santé des infusions végétales dans le traitement des pathologies à virus : aspects pratiques et théoriques concernant la Covid-19 (synthèse bibliographique)." Phytothérapie 19, no. 3 (June 2021): 134–41. http://dx.doi.org/10.3166/phyto-2021-0284.
Ye, Zhikang, Ying Wang, Luis Enrique Colunga-Lozano, Manya Prasad, Wimonchat Tangamornsuksan, Bram Rochwerg, Liang Yao, et al. "Efficacité et innocuité des corticostéroïdes dans le traitement de la COVID-19 selon des données pour la COVID-19, d’autres infections aux coronavirus, l’influenza, la pneumonie extrahospitalière et le syndrome de détresse respiratoire aiguë : revue systématique et méta-analyse." Canadian Medical Association Journal 192, no. 47 (November 22, 2020): E1571—E1584. http://dx.doi.org/10.1503/cmaj.200645-f.
Дисертації з теми "Infections à coronavirus – traitement médicamenteux":
Meunier, Thomas. "Étude des mécanismes d’action de nouveaux inhibiteurs de coronavirus humains." Thesis, Université de Lille (2018-2021), 2021. http://www.theses.fr/2021LILUS057.
Coronaviruses are enveloped RNA viruses infecting mammals and birds. Four coronaviruses causing mild diseases, like common cold, have been described in human, HCoV-OC43, HCoV-229E, HCoV-NL63 and HCoV-HKU1. During the last two decades, three new, highly pathogenic coronaviruses have been identified the SARS-CoV (Severe Acute Respiratory Syndrom) in 2003, the MERS-CoV (Middle East Respiratory Syndrome) in 2012 and recently the SARS-CoV-2 in December 2019. The COVID-19 global outbreak caused by SARS-CoV-2, highlighted the lack of specific antiviral available against this family of virus. The team of Dr Karin SERON from the Cellular and Molecular Virology laboratory of the Center for Infection and Immunity of Lille, is specialized in the identification of antiviral compounds from natural origin. Indeed, plants are a source of natural therapeutic compounds and many plants are still being used in traditional medicine. The aim of my thesis was to identify natural antiviral agents against highly pathogenic human coronaviruses with the help of the knowledge and tools developed by the laboratory. My first project was carried out in collaboration with the group of Dr Simon Bordage from the Pharmacognosy laboratory of the Faculty of Pharmacy of Lille directed by Pr Sevser Sahpaz. Plant extracts from Ivorian plants used it traditional medicine were tested against the coronavirus HCoV-229E and we selected the most active, the Mallotus oppositifollius extract. After bio-guided fractionation, the active compound was isolated and characterized, the pheophorbide a (Pba). Pba is able to inhibit the infection of HCoV-229E and highly pathogenic coronaviruses MERS-CoV and SARS-CoV-2 (IC50 = 0.18 μM) as well as other enveloped viruses using a photo-dynamic inactivation mechanism. Pba targets the viral envelop and inhibits the fusion step. Pba is the first described natural antiviral against SARS-CoV-2 with direct photosensitive virucidal activity. This molecule could potentially be used in therapy or as disinfectant. My second project was about an anthocyanidin, the delphinidin, identified in the laboratory for its antiviral activity against hepatitis C virus. We showed that delphinidin is an entry inhibitor of coronaviruses in a dose-dependent manner for HCoV-229E, MERS-CoV and SARS-CoV-2 (IC50 = 16-20 μM). Our results show that delphinidin targets the glycosylation sites on the surface protein S. Thanks to a collaboration with the laboratory of Medicinal and Bioorganic Chemistry of Strasbourg, led by Dr Mourad Elhabiri, delphinidin synthetic derivates were screened in order to identify compounds with higher antiviral capacities. We thereby identify an active compound against HCoV-229E with a lower IC50 than delphinidin (IC50 = 0.06 μM). Surprisingly, its mechanism of action seems to be different than delphinidin with an activity at the replication step.In conclusion, during my thesis I was able to identify new natural antivirals against human coronaviruses, and in particular SARS-CoV-2, with novel mechanisms of action. This work may serve as a basis for obtaining molecules that can be used in the future for the treatment of coronavirus diseases
Grall, Nathalie. "Emergence, dissémination et contrôle de la résistance aux beta-lactamines dans le microbiote intestinal." Sorbonne Paris Cité, 2015. http://www.theses.fr/2015USPCC145.
Antibiotic resistance has reached a worrying level in a context of continuai decline in the marketing of new molecules. The intestinal microbiota plays a major role in the emergence and spread of resistance, but the mechanisms involved are not ail understood. In the present work, we focused on the impact of p-lactams, the most commonly used class of antibiotic, on this microbiota. First we investigated the changes induced by imipenem, last-resort antibiotic, in the microbiota of multi-treated patients with an already altered microbiota. In these circumstances, additional changes of the microbiota are difficult to highlight, both by culture and metagenomics. This antibiotic, which have an admittedly low fecal excretion, is nonetheless recognized as a risk factor for infection with resistant bacteria. This work shows the limitations of current methods of microbiota characterization, whose sensitivity and depth of analysis need to be improved. Another poorly studied issue is the dissemination of resistance in the absence of selective pressure. We studied it quantitatively in natural conditions, by trapping small wild mammals at various distances from a single point of antibiotic use in a remote village of the Amazonian forest. Our results showed that acquired resistance to P-lactams do not spread in the wild in the absence of selective pressure, which is a strong incentive to control the diffusion of antibiotics in the environment. Eventually, we showed that it was possible to minimize the impact of antibiotics on intestinal microbiota, by inactivating antibiotics residues in the colon by adsorption. Indeed this strategy has allowed to partially restore resistance to colonization by a cefotaxime-resistant strain of Klebsiella pneumoniae in mice treated with cefotaxime. Overall, our work has clarified several aspects of the impact of p-lactams on intestinal microbiota and opened an innovative way to prevent this impact, which needs to be explored further
Okdah, Liliane. "Gestion patrimoniale des anciens agents antimicrobiens en les criblant contre des bactéries multi-résistantes modernes." Thesis, Aix-Marseille, 2017. http://www.theses.fr/2017AIXM0593.
The emergence of beta-lactam and carbapenem resistant bacteria, resulted in the reintroduction of colistin as an agent of last resort to treat infections caused by these bacteria. However, chromosomal resistances and more recently plasmidic to colistin appeared. This problem of multidrug-resistant bacteria subsequently triggered the publication of alarming articles on the dangers of these germs. To answer the media dramatization related to this problem, my thesis project aims to propose therapeutic strategies to treat infections due to multiresistant bacteria.Initially, we tested the activity of a large panel including old antibiotics against carbapenem resistant bacteria and others resistant to colistin. Several families of antibiotics have been effective against these two types of resistant bacteria.In a second step, we evaluated the activity of combined antibiotics in order to detect a synergistic action. Two synergistic combinations were retained: colistin + sulfadiazine and colistin + fusidic acid. These combinations of antibiotics have shown a bactericidal effect on a collection of Gram-negative colistin-resistant bacteria, independent of the resistance mechanism
Ndziessi, Gilbert. "Impact des traitements antirétroviraux sur le risque de transmission sexuelle du VIH en Afrique Subsaharienne : le cas du Cameroun." Thesis, Aix-Marseille, 2013. http://www.theses.fr/2013AIXM5016/document.
To evaluate the evolution and factors associated with sexual behavior among PLWHA exposed to antiretroviral therapy in sub-Saharan Africa. Data collected as part of a randomized trial conducted in nine rural district hospitals in Cameroon. 459 PLWHA eligible for treatment included and followed for 24 months. Mixed effects logistic regression used to analyze factors associated with different response variables studied. Proportion of patients sexually active increased from 32% at baseline to 56% after 24 months of treatment. An additional 6 months increase of the time since initiation of treatment increase in 30% the probability of reporting sexual activity. Proportion of patients with sexual risk behavior (SRB) decreased significantly from 76% at baseline to 66% at 24 months and patient obervants to treatment were less likely to report CSR. Proportion of patients likely to transmit HIV through sexual intercourse (STVIH) decrease from 76% at baseline to 27% after 24 months of HAART. Analyses shown that increasing in 6 months of time since initiation of treatment reduced STVIH by 66%. My dissertation show a positive impact of ART on sexual activity, CSR and STVIH among PLWHA, suggesting a positive effect of exposure to HAART on the prevention of sexual transmission of HIV. However, the potential risk of transmission of HIV persists requiring strengthening risk reduction interventions in HAART access programs
Книги з теми "Infections à coronavirus – traitement médicamenteux":
Phillips, I. Issues in the Treatment of Upper Respiratory Tract Infections. Royal Society of Medicine, 1988.
Project Inform (San Francisco, Calif.), ed. The HIV drug book. 2nd ed. New York: Pocket Books, 1998.